{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:08:47Z","timestamp":1788970127121,"version":"build-2803163510"},"reference-count":58,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Lurasidone ((3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione) is a second-generation antipsychotic approved for schizophrenia and mood disorders. Adolescents and children with bipolar disorder receive treatments that expose them to weight gain and metabolic syndrome. Lurasidone is relatively free from such side effects, so it may constitute a useful alternative for the treatment of these patients. We focused on the use of lurasidone in children and adolescents with bipolar disorder. Methods: On 11 June 2025, we used the following strategy on PubMed: lurasidone AND (\u201cbipolar disorder\u201d OR \u201cbipolar depression\u201d OR mania OR manic). We filtered for humans and ages 0\u201318 years and included case reports and clinical studies. Similar strategies adapted to each database were used to carry out our systematic review on CINAHL, PsycINFO\/PsycARTICLES, Scopus, and the ClinicalTrials.gov register on the same date. We excluded reports without children\/adolescent participants, those grouping adult participants with children\/adolescents without providing data separately, reviews, and opinions\/editorials with no data. Eligibility was determined through Delphi rounds; it was required that consensus was reached among all authors. We followed the PRISMA-2020 Statement. Results: Our search produced 38 results on PubMed on 11 June 2025. We included four case reports\/series and five studies. One additional eligible study emerged from our Scopus inquiry, raising the number of eligible studies to six. One case series was moderately positive; one case report was neutral, another was positive, and one reported the induction of mania. The six longitudinal studies involved 16,735 participants and showed generally good efficacy. Conclusions: The use of lurasidone in adolescents\/children with bipolar disorder obtains favorable results regarding the excitatory and depressive symptoms of bipolar disorder with no significant side effects.<\/jats:p>","DOI":"10.3390\/ph18070979","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:55:43Z","timestamp":1751442943000},"page":"979","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lurasidone for Pediatric Bipolar Disorder: A Systematic Review"],"prefix":"10.3390","volume":"18","author":[{"given":"Alexia","family":"Koukopoulos","sequence":"first","affiliation":[{"name":"Department of Life Science, Health and Health Professions, Link Campus University, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9046-1751","authenticated-orcid":false,"given":"Claudia","family":"Calderoni","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy"},{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-6324","authenticated-orcid":false,"given":"Georgios D.","family":"Kotzalidis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy"},{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-5331","authenticated-orcid":false,"given":"Tommaso","family":"Callovini","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy"},{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Moccia","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy"},{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Montanari","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy"},{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna","family":"Autullo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy"},{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-7494","authenticated-orcid":false,"given":"Alessio","family":"Simonetti","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy"},{"name":"Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8254-9299","authenticated-orcid":false,"given":"Mario","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy"},{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-9230","authenticated-orcid":false,"given":"Giovanni","family":"Camardese","sequence":"additional","affiliation":[{"name":"Department of Life Science, Health and Health Professions, Link Campus University, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9767-8752","authenticated-orcid":false,"given":"Gabriele","family":"Sani","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy"},{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delfina","family":"Janiri","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy"},{"name":"Department of Neuroscience, Section of Psychiatry, Universit\u00e0 Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","unstructured":"American Psychiatric Association (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text-Revision (DSM-5-TR), American Psychiatric Press."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.wpsyc.2012.01.006","article-title":"Age at onset versus family history and clinical outcomes in 1665 international bipolar-I disorder patients","volume":"11","author":"Baldessarini","year":"2012","journal-title":"World Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/10673229509017185","article-title":"Pediatric-onset bipolar disorder: A neglected clinical and public health problem","volume":"3","author":"Faedda","year":"1995","journal-title":"Harv. Rev. Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/camh.12021","article-title":"Bipolar disorder in children and adolescents","volume":"18","author":"Birmaher","year":"2013","journal-title":"Child Adolesc. Ment. Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jad.2019.04.076","article-title":"Early and late cortical reactivity to passively viewed emotional faces in pediatric bipolar disorder","volume":"253","author":"Simonetti","year":"2019","journal-title":"J. Affect. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Janiri, D., Moccia, L., Conte, E., Palumbo, L., Chieffo, D.P.R., Fredda, G., Menichincheri, R.M., Balbi, A., Kotzalidis, G.D., and Sani, G. (2021). Emotional dysregulation, temperament and lifetime suicidal ideation among youths with mood disorders. J. Pers. Med., 11.","DOI":"10.3390\/jpm11090865"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106521","DOI":"10.1016\/j.chiabu.2023.106521","article-title":"Primary emotional systems, childhood trauma, and suicidal ideation in youths with bipolar disorders","volume":"146","author":"Janiri","year":"2023","journal-title":"Child Abuse Negl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jad.2024.11.013","article-title":"Intergenerational transmission of childhood trauma in youths with mood disorders and their parents","volume":"370","author":"Montanari","year":"2025","journal-title":"J. Affect. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/bdi.12516","article-title":"Amygdala and hippocampus volumes are differently affected by childhood trauma in patients with bipolar disorders and healthy controls","volume":"19","author":"Janiri","year":"2017","journal-title":"Bipolar Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jad.2019.04.071","article-title":"Hippocampal subfield volumes and childhood trauma in bipolar disorders","volume":"253","author":"Janiri","year":"2019","journal-title":"J. Affect. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/acps.13591","article-title":"Comorbidity in pediatric bipolar disorder: An unmet challenge in need of treatment studies","volume":"148","author":"Goldstein","year":"2023","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_13","first-page":"13","article-title":"Update on newer antipsychotic drugs","volume":"49","author":"Howland","year":"2011","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"111736","DOI":"10.1016\/j.ejmech.2019.111736","article-title":"Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect","volume":"183","author":"Chodkowski","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jpsychires.2016.03.012","article-title":"Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts","volume":"78","author":"Suppes","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/14656566.2019.1695777","article-title":"Evaluating lurasidone as a treatment option for bipolar disorder","volume":"21","author":"Ali","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaac.2017.10.006","article-title":"Efficacy and safety of lurasidone in children and adolescents with bipolar i depression: A double-blind, placebo-controlled study","volume":"56","author":"DelBello","year":"2017","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2174\/1570159X15666170630163616","article-title":"Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects","volume":"16","author":"Siafis","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1016\/j.clinthera.2015.11.001","article-title":"Pharmacokinetics and tolerability of lurasidone in children and adolescents with psychiatric disorders","volume":"37","author":"Findling","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40262-016-0465-5","article-title":"Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: A systematic review of the published literature","volume":"56","author":"Greenberg","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.2174\/1381612827666210804110853","article-title":"Efficacy and safety of lurasidone in children and adolescents: Recommendations for clinical management and future research","volume":"27","author":"Amerio","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1089\/cap.2020.0018","article-title":"Lurasidone in children and adolescents with bipolar depression presenting with mixed (subsyndromal hypomanic) features: Post hoc analysis of a randomized placebo-controlled trial","volume":"30","author":"Singh","year":"2020","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1089\/cap.2021.0040","article-title":"Tolerability, safety, and effectiveness of two years of treatment with lurasidone in children and adolescents with bipolar depression","volume":"31","author":"DelBello","year":"2021","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.12809\/eaap2040","article-title":"Lurasidone-induced manic switch in an adolescent with bipolar I disorder: A case report","volume":"31","author":"Nair","year":"2021","journal-title":"East Asian Arch. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Aromataris, E., and Munn, Z. (2020). Chapter 7: Systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis, Joanna Briggs Institute. Available online: https:\/\/synthesismanual.jbi.global.","DOI":"10.46658\/JBIRM-17-01"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/head.12246","article-title":"The CARE guidelines: Consensus-based clinical case reporting guideline development","volume":"53","author":"Gagnier","year":"2013","journal-title":"Headache"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1089\/cap.2018.0046","article-title":"Lurasidone in children and adolescents: Systematic review and case report","volume":"28","author":"Channing","year":"2018","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/cap.2019.0029","article-title":"Use of suvorexant for sleep regulation in an adolescent with early-onset bipolar disorder","volume":"29","author":"Prieto","year":"2019","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0897190021997011","article-title":"Lurasidone for adolescents with complex mental disorders: A case series","volume":"35","author":"Mole","year":"2022","journal-title":"J. Pharm. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1080\/13696998.2021.1993862","article-title":"Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: A real-world retrospective claims database study","volume":"24","author":"Kadakia","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2174\/1570159X20666220927112625","article-title":"Sleep disturbance, irritability, and response to lurasidone treatment in children and adolescents with bipolar depression","volume":"21","author":"Singh","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Diao, X., Luo, D., Wang, D., Lai, J., Li, Q., Zhang, P., Huang, H., Wu, L., Lu, S., and Hu, S. (2022). Lurasidone versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study. Pharmaceuticals, 15.","DOI":"10.3390\/ph15111403"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eurpsy.2018.05.009","article-title":"Psychopathological characteristics and adverse childhood events are differentially associated with suicidal ideation and suicidal acts in mood disorders","volume":"53","author":"Janiri","year":"2018","journal-title":"Eur. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/1570159X21666230213155249","article-title":"Childhood trauma and self-harm in youths with bipolar disorders","volume":"22","author":"Janiri","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euroneuro.2019.06.008","article-title":"Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone","volume":"29","author":"Corponi","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/cap.2021.0031","article-title":"Second-generation antipsychotics in management of acute pediatric bipolar depression: A systematic review and meta-analysis","volume":"31","author":"Patel","year":"2021","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaac.2021.03.021","article-title":"Systematic review and network meta-analysis: Efficacy and safety of second-generation antipsychotics in youths with bipolar depression","volume":"61","author":"DelBello","year":"2022","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"115637","DOI":"10.1016\/j.psychres.2023.115637","article-title":"Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis","volume":"332","author":"Feng","year":"2024","journal-title":"Psychiatry Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.5498\/wjp.v6.i4.399","article-title":"Treatment-adherence in bipolar disorder: A patient-centred approach","volume":"6","author":"Chakrabarti","year":"2016","journal-title":"World J. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40263-014-0176-0","article-title":"Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: A nationwide register-based cohort study in Denmark","volume":"28","author":"Pasternak","year":"2014","journal-title":"CNS Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40273-016-0405-0","article-title":"Cost-utility analysis of lurasidone versus aripiprazole in adults with schizophrenia","volume":"34","author":"Rajagopalan","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.17116\/jnevro202012006282","article-title":"\u0424\u0430\u0440\u043c\u0430\u043ao\u044d\u043ao\u043do\u043c\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043do\u0441\u0442\u044c \u043f\u0440\u0438\u043c\u0435\u043d\u0435\u043d\u0438\u044f \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430 \u041b\u0443\u0440\u0430\u0437\u0438\u0434o\u043d \u043f\u0440\u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0448\u0438\u0437o\u0444\u0440\u0435\u043d\u0438\u0438 [The pharmacoeconomic efficacy of Lurasidone in the treatment of schizophrenia]","volume":"120","author":"Zyryanov","year":"2020","journal-title":"Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/pcn.13137","article-title":"Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression","volume":"74","author":"Kato","year":"2020","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1359786806066040","article-title":"The 5-HT2C receptor and antipsychoticinduced weight gain\u2013mechanisms and genetics","volume":"20","author":"Reynolds","year":"2006","journal-title":"J. Psychopharmacol."},{"key":"ref_50","first-page":"2143","article-title":"Lurasidone for the treatment of bipolar depression: An evidence-based review","volume":"11","author":"Franklin","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-3-642-24716-3_16","article-title":"5-HT2C receptor agonists and the control of appetite","volume":"209","author":"Halford","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/NDT.S18059","article-title":"Critical appraisal of lurasidone in the management of schizophrenia","volume":"8","author":"Caccia","year":"2012","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/0269881109348157","article-title":"Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: A post hoc analysis of pooled data from short- and long-term aripiprazole trials","volume":"24","author":"Kane","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2174\/1570159X14666161208153644","article-title":"Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges","volume":"15","author":"Salem","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4088\/JCP.14m09410","article-title":"Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: Post hoc analysis of a randomized placebo-controlled trial","volume":"76","author":"McIntyre","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Danek, P.J., and Daniel, W.A. (2022). The atypical antipsychotic lurasidone affects brain but not liver cytochrome P450 2D (CYP2D) activity. A comparison with other novel neuroleptics and significance for drug treatment of schizophrenia. Cells, 11.","DOI":"10.3390\/cells11213513"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Chen, C.K., Wu, L.S., Huang, M.C., Kuo, C.J., and Cheng, A.T. (2022). Antidepressant treatment and manic switch in bipolar I disorder: A clinical and molecular genetic study. J. Pers. Med., 12.","DOI":"10.3390\/jpm12040615"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"82","DOI":"10.9740\/mhc.2024.04.082","article-title":"Pharmacologic treatment of bipolar disorder and comorbid adult attention-deficit\/hyperactivity disorder","volume":"14","author":"Vallabh","year":"2024","journal-title":"Ment. Health Clin."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/979\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:38Z","timestamp":1760032898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":58,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ph18070979"],"URL":"https:\/\/doi.org\/10.3390\/ph18070979","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}